Europe’s biomedical researchers prepare to gather in Belgium
A European Institute for Biomedical Imaging Research (EIBIR)/European Network for Cell Imaging and Tracking Expertise (ENCITE) educational workshop, called “Cells at work: Imaging in health and disease,” will take place May 18-19 at the University of Mons in Belgium.
A European Institute for Biomedical Imaging Research (EIBIR)/European Network for Cell Imaging and Tracking Expertise (ENCITE) educational workshop, called “Cells at work: Imaging in health and disease,” will take place May 18-19 at the University of Mons in Belgium.
ENCITE is a collaborative project coordinated by EIBIR. It is related to the theme “Cooperation health: in vivo image-guidance for cell therapy,” and is supported by the European Commission within the 7th Framework Programme for Research. It started in June 2009, thanks to a financial contribution of €12 million. ENCITE is a four-year project and has 29 project partners from 11 countries with expertise in the field of cell imaging.
The mission of the project is to develop and test new MR and optical imaging methods and biomarkers to get a more comprehensive picture of cell fate and reactions of the immune system, and ultimately to improve and further develop cell therapy for the benefit of the European patient. Details on the interim results can be found here.
The deadline to register is April 20.
For more information, please contact: office@eibir.org.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
